文献速递产科母胎医学

双胎妊娠cfDNA筛查21/18/13三体的队列研究与荟萃分析

Cell-free DNA testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10-14 weeks and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-07-10

该研究更新了FMF前瞻性双胎妊娠10-14周cfDNA筛查数据,并纳入12项文献研究进行荟萃分析。FMF队列1442例双胎中1367例获得结果,1272例纳入分析,21三体20例、18三体10例、13三体2例。荟萃分析显示21三体合并检出率99.0%、假阳性率0.02%,18三体检出率92.8%、假阳性率0.01%,13三体检出率94.7%、假阳性率0.10%。

要点

  • 双胎妊娠cfDNA对21三体检出率高但低于单胎,假阳性率同样低。
  • 18三体和13三体病例数过少,预测性能无法准确评估。
  • FMF队列中cfDNA对21三体检出19/20(95.0%),18三体9/10(90.0%),13三体1/2(50.0%)。

核心结论

  • 双胎妊娠cfDNA筛查21三体检出率高但低于单胎,假阳性率同样低。
  • 18三体和13三体病例数过少,无法准确评估cfDNA预测性能。

研究设计与样本

  • FMF前瞻性队列:双胎妊娠10+0至14+1周行Harmony产前检测筛查21/18/13三体。
  • 系统检索MEDLINE、EMBASE、CENTRAL、ClinicalTrials.gov和ICTRP,纳入12项验证或实施研究。
  • 荟萃分析结合FMF数据与文献数据,研究注册于PROSPERO。

主要发现

  • FMF队列1442例双胎中1367例(94.8%)获得cfDNA结果,1272例纳入分析。
  • FMF队列中21三体检出19/20(95.0%),18三体9/10(90.0%),13三体1/2(50.0%),非三体1235/1240(99.6%)。
  • 合并分析21三体137例与非三体7507例,检出率99.0%(95%CI 92.0-99.9%),假阳性率0.02%(95%CI 0.001-0.43%)。
  • 合并分析18三体50例与非三体6840例,检出率92.8%(95%CI 77.6-98.0%),假阳性率0.01%(95%CI 0.00-0.44%)。
  • 合并分析13三体11例与非三体6290例,检出率94.7%(95%CI 9.14-99.97%),假阳性率0.10%(95%CI 0.03-0.39%)。

临床怎么用

  • 双胎妊娠可考虑cfDNA筛查21三体,但需告知检出率低于单胎。
  • 18三体和13三体因数据有限,cfDNA结果解释需谨慎。

局限性

  • 18三体和13三体病例数过少,预测性能评估不准确。
  • FMF队列中95例因无已知核型或失访被排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To expand the limited knowledge on cell-free DNA (cfDNA) analysis of maternal blood for trisomies 21, 18 and 13 in twin pregnancy by updating the data from The Fetal Medicine Foundation (FMF) on prospective first-trimester screening and those identified in a systematic review of the literature. METHODS: The FMF data were derived from prospective screening for trisomies 21, 18 and 13 in twin pregnancies at 10 + 0 to 14 + 1 weeks' gestation using the Harmony® prenatal test. A search of MEDLINE, EMBASE, CENTRAL (The Cochrane Library), ClinicalTrials.gov and the International Clinical Trials Registry Platform (World Health Organization) was carried out to identify all peer-reviewed publications on clinical validation or implementation of maternal cfDNA testing for trisomies 21, 18 and 13 in twin pregnancy, irrespective of gestational age at testing, in which data on pregnancy outcome were provided for at least 85% of the study population. Meta-analysis was performed using the FMF data and data from the studies identified by the literature search. This review was registered in the PROSPERO international database for systematic reviews RESULTS: In the FMF study, cfDNA testing was carried out in 1442 twin pregnancies and a result was obtained, after first or second sampling, in 1367 (94.8%) cases. In 93.1% (1272/1367) of cases, there was prenatal or postnatal karyotyping or birth of phenotypically normal babies; 95 cases were excluded from further analysis either because the pregnancy ended in termination, miscarriage or stillbirth with no known karyotype (n = 56) or there was loss to follow-up (n = 39). In the 1272 pregnancies included in the study, there were 20 cases with trisomy 21, 10 with trisomy 18, two with trisomy 13 and 1240 without trisomy 21, 18 or 13. The cfDNA test classified correctly 19 (95.0%) of the 20 cases of trisomy 21, nine (90.0%) of the 10 cases of trisomy 18, one (50.0%) of the two cases of trisomy 13 and 1235 (99.6%) of the 1240 cases without any of the three trisomies. The literature search identified 12 relevant studies, excluding our papers because their data are included in the current study. In the combined populations of our study and the 12 studies identified by the literature search, there were 137 trisomy-21 and 7507 non-trisomy-21 twin pregnancies; the pooled weighted detection rate (DR) and false-positive rate (FPR) were 99.0% (95% CI, 92.0-99.9%) and 0.02% (95% CI, 0.001-0.43%), respectively. In the combined total of 50 cases of trisomy 18 and 6840 non-trisomy-18 pregnancies, the pooled weighted DR and FPR were 92.8% (95% CI, 77.6-98.0%) and 0.01% (95% CI, 0.00-0.44%), respectively. In the combined total of 11 cases of trisomy 13 and 6290 non-trisomy-13 pregnancies, the pooled weighted DR and FPR were 94.7% (95% CI, 9.14-99.97%) and 0.10% (95% CI, 0.03-0.39%), respectively. CONCLUSIONS: In twin pregnancy, the reported DR of trisomy 21 by cfDNA testing is high, but lower than that in singleton pregnancy, whereas the FPR appears to be equally low. The number of cases of trisomy 18 and more so trisomy 13 was too small for accurate assessment of the predictive performance of the cfDNA test. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Judah H, Gil MM, Syngelaki A, et al. Cell-free DNA testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10-14 weeks and meta-analysis. Ultrasound Obstet Gynecol. 2021. PMID: 33838069. doi:10.1002/uog.23648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。